TipRanks
Merck & Company (CH:6MK)
:6MK
Switzerland Market
6MK
Merck & Company
RESEARCH TOOLSreports

Merck & Company (6MK) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

6MK Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
14 Buy
5 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6MK Stock 12 Month Forecast

Average Price Target

CHF131.17
▲(35.81% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is CHF131.17 with a high forecast of CHF147.11 and a low forecast of CHF85.82. The average price target represents a 35.81% change from the last price of CHF96.58.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","100":"CHF100","116":"CHF116","132":"CHF132","148":"CHF148"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":147.112308,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF147.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":131.16688683333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF131.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.815513,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF85.82</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,100,116,132,148],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.578,100.46525446153846,104.35250892307693,108.23976338461539,112.12701784615385,116.01427230769231,119.90152676923077,123.78878123076925,127.67603569230769,131.56329015384617,135.45054461538462,139.3377990769231,143.22505353846157,{"y":147.112308,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.578,99.23868360256411,101.89936720512821,104.5600508076923,107.22073441025641,109.88141801282052,112.54210161538462,115.20278521794873,117.86346882051282,120.52415242307693,123.18483602564103,125.84551962820512,128.50620323076924,{"y":131.16688683333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.578,95.75011638461538,94.92223276923077,94.09434915384615,93.26646553846155,92.43858192307692,91.6106983076923,90.7828146923077,89.95493107692307,89.12704746153845,88.29916384615385,87.47128023076922,86.64339661538462,{"y":85.815513,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":96.578,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF147.11Average Price TargetCHF131.17Lowest Price TargetCHF85.82
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CH:6MK
Trung Huynh
RBC Capital
RBC Capital
CHF122.59
Hold
26.93%
Upside
Reiterated
09/14/26
RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)
DBS Analyst forecast on CH:6MK
Nico Chen
DBS
DBS
CHF147.11
Buy
52.32%
Upside
Reiterated
09/11/26
DBS Keeps Their Buy Rating on Merck & Company (MRK)
Bank of America Securities Analyst forecast on CH:6MK
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF135.67
Buy
40.47%
Upside
Reiterated
09/10/26
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA), Merck & Company (NYSE: MRK) and Pacific Biosciences (NASDAQ: PACB)
HSBC Analyst forecast on CH:6MK
Rajesh Kumar
HSBC
HSBC
CHF122.59→CHF140.57
Buy
45.55%
Upside
Reiterated
09/10/26
Merck price target raised to $172 from $150 at HSBCMerck price target raised to $172 from $150 at HSBC
Leerink Partners Analyst forecast on CH:6MK
Daina Graybosch
Leerink Partners
Leerink Partners
CHF103.8→CHF131.58
Buy
36.24%
Upside
Assigned
09/10/26
Merck price target raised to $161 from $127 at LeerinkMerck price target raised to $161 from $127 at Leerink
Guggenheim Analyst forecast on CH:6MK
Vamil Divan
Guggenheim
Guggenheim
CHF119.32→CHF138.94
Buy
43.86%
Upside
Reiterated
09/08/26
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Merck & Company (NYSE: MRK) and Royalty Pharma (NASDAQ: RPRX)
Bernstein Analyst forecast on CH:6MK
Courtney Breen
Bernstein
Bernstein
CHF85.82
Hold
-11.15%
Downside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Intellia Therapeutics (NASDAQ: NTLA) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Barclays Analyst forecast on CH:6MK
Emily Field
Barclays
Barclays
CHF132.59→CHF142.06
Hold
47.09%
Upside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on CH:6MK
Mohit Bansal
Wells Fargo
Wells Fargo
CHF122.59→CHF138.94
Buy
43.86%
Upside
Assigned
09/04/26
Merck price target raised to $170 from $150 at Wells FargoMerck price target raised to $170 from $150 at Wells Fargo
Scotiabank Analyst forecast on CH:6MK
Louise Chen
Scotiabank
Scotiabank
CHF126.68
Buy
31.17%
Upside
Reiterated
08/31/26
Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)
Wolfe Research Analyst forecast on CH:6MK
Alexandria Hammond
Wolfe Research
Wolfe Research
CHF126.68→CHF147.11
Buy
52.32%
Upside
Reiterated
08/25/26
Merck price target raised to $180 from $155 at Wolfe ResearchMerck price target raised to $180 from $155 at Wolfe Research
Argus Research Analyst forecast on CH:6MK
Jasper Hellweg
Argus Research
Argus Research
CHF118.51→CHF138.94
Buy
43.86%
Upside
Reiterated
08/24/26
Merck price target raised to $170 from $145 at ArgusMerck price target raised to $170 from $145 at Argus
BMO Capital Analyst forecast on CH:6MK
Evan Seigerman
BMO Capital
BMO Capital
CHF116.06→CHF138.94
Buy
43.86%
Upside
Reiterated
08/20/26
BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)
Goldman Sachs Analyst forecast on CH:6MK
Asad Haider
Goldman Sachs
Goldman Sachs
CHF114.42→CHF130.77
Buy
35.40%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Moderna (NASDAQ: MRNA) and Akari Therapeutics (NASDAQ: AKTX)
UBS Analyst forecast on CH:6MK
Michael Yee
UBS
UBS
CHF118.51→CHF143.03
Buy
48.09%
Upside
Reiterated
08/20/26
Merck price target raised to $175 from $145 at UBSMerck price target raised to $175 from $145 at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CH:6MK
Trung Huynh
RBC Capital
RBC Capital
CHF122.59
Hold
26.93%
Upside
Reiterated
09/14/26
RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)
DBS Analyst forecast on CH:6MK
Nico Chen
DBS
DBS
CHF147.11
Buy
52.32%
Upside
Reiterated
09/11/26
DBS Keeps Their Buy Rating on Merck & Company (MRK)
Bank of America Securities Analyst forecast on CH:6MK
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF135.67
Buy
40.47%
Upside
Reiterated
09/10/26
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA), Merck & Company (NYSE: MRK) and Pacific Biosciences (NASDAQ: PACB)
HSBC Analyst forecast on CH:6MK
Rajesh Kumar
HSBC
HSBC
CHF122.59→CHF140.57
Buy
45.55%
Upside
Reiterated
09/10/26
Merck price target raised to $172 from $150 at HSBCMerck price target raised to $172 from $150 at HSBC
Leerink Partners Analyst forecast on CH:6MK
Daina Graybosch
Leerink Partners
Leerink Partners
CHF103.8→CHF131.58
Buy
36.24%
Upside
Assigned
09/10/26
Merck price target raised to $161 from $127 at LeerinkMerck price target raised to $161 from $127 at Leerink
Guggenheim Analyst forecast on CH:6MK
Vamil Divan
Guggenheim
Guggenheim
CHF119.32→CHF138.94
Buy
43.86%
Upside
Reiterated
09/08/26
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Merck & Company (NYSE: MRK) and Royalty Pharma (NASDAQ: RPRX)
Bernstein Analyst forecast on CH:6MK
Courtney Breen
Bernstein
Bernstein
CHF85.82
Hold
-11.15%
Downside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Intellia Therapeutics (NASDAQ: NTLA) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Barclays Analyst forecast on CH:6MK
Emily Field
Barclays
Barclays
CHF132.59→CHF142.06
Hold
47.09%
Upside
Reiterated
09/07/26
Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on CH:6MK
Mohit Bansal
Wells Fargo
Wells Fargo
CHF122.59→CHF138.94
Buy
43.86%
Upside
Assigned
09/04/26
Merck price target raised to $170 from $150 at Wells FargoMerck price target raised to $170 from $150 at Wells Fargo
Scotiabank Analyst forecast on CH:6MK
Louise Chen
Scotiabank
Scotiabank
CHF126.68
Buy
31.17%
Upside
Reiterated
08/31/26
Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)
Wolfe Research Analyst forecast on CH:6MK
Alexandria Hammond
Wolfe Research
Wolfe Research
CHF126.68→CHF147.11
Buy
52.32%
Upside
Reiterated
08/25/26
Merck price target raised to $180 from $155 at Wolfe ResearchMerck price target raised to $180 from $155 at Wolfe Research
Argus Research Analyst forecast on CH:6MK
Jasper Hellweg
Argus Research
Argus Research
CHF118.51→CHF138.94
Buy
43.86%
Upside
Reiterated
08/24/26
Merck price target raised to $170 from $145 at ArgusMerck price target raised to $170 from $145 at Argus
BMO Capital Analyst forecast on CH:6MK
Evan Seigerman
BMO Capital
BMO Capital
CHF116.06→CHF138.94
Buy
43.86%
Upside
Reiterated
08/20/26
BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)
Goldman Sachs Analyst forecast on CH:6MK
Asad Haider
Goldman Sachs
Goldman Sachs
CHF114.42→CHF130.77
Buy
35.40%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Moderna (NASDAQ: MRNA) and Akari Therapeutics (NASDAQ: AKTX)
UBS Analyst forecast on CH:6MK
Michael Yee
UBS
UBS
CHF118.51→CHF143.03
Buy
48.09%
Upside
Reiterated
08/20/26
Merck price target raised to $175 from $145 at UBSMerck price target raised to $175 from $145 at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
AXGNAxoGen
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months
Mohit BansalWells Fargo
Success Rate
12/16 ratings generated profit
75%
Average Return
+7.88%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.88% per trade.
1 Year
Mohit BansalWells Fargo
Success Rate
14/16 ratings generated profit
88%
Average Return
+21.07%
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +21.07% per trade.
2 Years
Vamil DivanGuggenheim
Success Rate
20/21 ratings generated profit
95%
Average Return
+34.47%
Copying Vamil Divan's trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +34.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6MK Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
1
1
0
0
0
Buy
49
43
44
52
46
Hold
18
18
16
16
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
68
62
60
68
58
In the current month, 6MK has received 46 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. 6MK average Analyst price target in the past 3 months is 131.17.
Each month's total comprises the sum of three months' worth of ratings.

6MK Financial Forecast

6MK Earnings Forecast

Next quarter’s earnings estimate for 6MK is CHF1.82 with a range of CHF1.64 to CHF1.98. The previous quarter’s EPS was -CHF0.11. 6MK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6MK is CHF1.82 with a range of CHF1.64 to CHF1.98. The previous quarter’s EPS was -CHF0.11. 6MK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Sales Forecast

Next quarter’s sales forecast for 6MK is CHF14.20B with a range of CHF13.73B to CHF14.62B. The previous quarter’s sales results were CHF13.59B. 6MK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.
Next quarter’s sales forecast for 6MK is CHF14.20B with a range of CHF13.73B to CHF14.62B. The previous quarter’s sales results were CHF13.59B. 6MK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Stock Forecast FAQ

What is CH:6MK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 131.17.
    What is CH:6MK’s upside potential, based on the analysts’ average price target?
    Merck & Company has 35.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Merck & Company a Buy, Sell or Hold?
          Merck & Company has a consensus rating of Moderate Buy, which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Merck & Company’s share price target?
            The average share price target for Merck & Company is 131.17. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF147.11 ,and the lowest forecast is CHF85.82. The average share price target represents 35.81% Increase from the current price of CHF96.58.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Merck & Company?
                To buy shares of CH:6MK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.